Onty utilizes similar Dendritic Cell Therapy to Prima,therefore the outcome may have an impact on Prima's shareprice and future prospects/confidence moving forward,positive or negative, as did Dendreons fall from grace..............
""Oncothyreon(ONTY_) will also live or die based on first-quarter clinical trial results. Final data from the phase III study of the lung cancer drug Stimuvax will be ready in the first quarter, Merck KGaA CEO Karl-Luwdwig Kley told Reuters last Thursday.
The German Merck is Oncothyreon's development partner for Stimuvax, a cancer immunotherapy. Oncothyreon shares were cut in half last March because an interim analysis of the Stimuvax lung cancer study wasn't robust enough to demonstrate a survival advantage. Expectations for Stimuvax are low right now, so Oncothyreon is another easy double if the cancer "vaccine" can buck the odds and win when the final results from the lung cancer study are announced.""
http://www.thestreet.com/story/11771273/1/first-90-days-of-2013-are-live-or-die-for-these-biotech-stocks.html?puc=yahoo&cm_ven=YAHOO
watch this space
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.025(6.33%) |
Mkt cap ! $598.3M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 42.0¢ | 39.5¢ | $890.1K | 2.163M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 127863 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 30850 | 2 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |